### Procter & Gamble - I.P. Division

SEP 1 5 2005

#### IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

# FACSIMILE TRANSMITTAL SHEET AND CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8

## TO: Official Application Related Correspondance - United States Patent and Trademark Office

Fax No. 571/273-8300 And Examiner Pryor 571/273-0621

Phone No.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on September 15, 2005, to the above-identified facsimile number.

(Signature)

FROM: James F. McBride

Fax No. 513-627-0260

Phone No. 513-627-0079

Listed below are the item(s) being submitted with this Certificate of Transmission:

1) Amendment transmittal - in duplicate

2) Amendment - 12 pgs.

Inventor(s): Haught al.

S.N.: 10/662644


Filed: September 15, 2003

Case: 8170XR

Number of Pages Including this Page: 15

Comments:

SEP 1 5 2005



#### IN THE UNITED STATES PATENT & TRADEMARK OFFICE RESPONSE/AMENDMENT

And Processes For Making Same

#### COMMISSIONER FOR PATENTS VIA FACSIMILE 571/273-8300

Dear Sir:

Transmitted herewith is an AMENDMENT for the patent application:

Application No.

10/662,644

Applicant(s)

Haught et al.

Filed

9/15/2003

Title

Non-Halogenated Antibacterial Agents

TC/A.U. Examiner Conf. No. 1600/1616 A. Pryor

9385 •

Docket No. Customer No. 8170XR 27752

- 1. [X] No additional fees (claims fees or extension fees) are known to be required.
- 2. [] The fee has been calculated as shown below:

OTHER THAN A

	(Col. 1)	(Col. 2)		(Col. 3)	SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA*	RATE	FEE
TOTAL	* 17	MINUS	** 20	<b>==</b> 0	x \$ 50 =	<u> </u>
INDEP.	* 3	MINUS	*** 3	= 0	x \$200 =	\$
	SENTATION OF MULTI		I.AIM		+ \$360 =	\$
FIRST FREA	ENTATION OF MOET	. <u> </u>		· · · · · · · · · · · · · · · · · · ·	TOTAL	\$

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the highest number of total claims previously paid for is less than 20, write "20" in this space.

  If the highest number of independent claims previously paid for is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment

- or the number of claims originally filed. 3. [X] The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated 9/7/05 in the above-identified application to preserve pendency of said application. The processing fee under 37 CFR §1.17 has been determined as follows: \$0 for a 0month extension of time.
  - 4. The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
    - Any patent application processing fees under 37 CFR §1.16. [x]
    - Any patent application processing fees under 37 CFR §1.17.
  - 5. The Director is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

THE PROCTER & GAMBLE COMPANY Signature James F. McBride

Date: September 15, 2005 Customer No. 27752

Registration No. 43,784

(513) 627-0079 (Transamd.doc) Revised 8/3/2005

#### IN THE UNITED STATES PATENT & TRADEMARK OFFICE RESPONSE/AMENDMENT

#### **COMMISSIONER FOR PATENTS** VIA FACSIMILE 571/273-8300

Dear Sir:

Transmitted herewith is an AMENDMENT for the patent application:

Application No.

10/662,644

Applicant(s)

Haught et al.

Filed

9/15/2003

Title

Non-Halogenated Antibacterial Agents

And Processes For Making Same

TC/A.U. Examiner 1600/1616 A. Pryor

Conf. No.

Docket No. Customer No. 8170XR 27752

9385

- 1. [X] No additional fees (claims fees or extension fees) are known to be required.
- 2. [] The fee has been calculated as shown below:

OTHER THAN A

	(Col. 1)		(Col. 2)	(Col. 3)	SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA*	RATE	FEE
TOTAL	* 17	MINUS	** 20	= 0	x \$ 50 =	\$
INDEP.	• 3	MINUS	*** 3	= 0	x \$200 =	\$
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$360 =	\$
FIRST FREE	SENTATION OF MOBIL	LUD Dar . C.			TOTAL	\$

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the highest number of total claims previously paid for is less than 20, write "20" in this space.

If the highest number of independent claims previously paid for is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

- 3. [X] The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated 9/7/05 in the above-identified application to preserve pendency of said application. The processing fee under 37 CFR §1.17 has been determined as follows: \$0 for a 0month extension of time.
- 4. The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
  - Any patent application processing fees under 37 CFR §1.16. [x]
  - Any patent application processing fees under 37 CFR §1.17.
- 5. The Director is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

THE PROOTER & GAMBLE COMPANY Signature James F. McBride

Date: September 15, 2005 Customer No. 27752

Registration No. 43,784

(Transamd.doc) Revised 8/3/2005

(513) 627-0079

CHILL

09-15-2005

4/15

SEP 1 5 2005

Appl. No. 10/662,644 Atty. Docket No. 8170XR Amdt. Dated September 15, 2005 Reply to Office Action of September 7, 2005 Customer No. 27752

Certification of Multing or Facalcula Transmission				
a transfer when I have consequently basis to expect that on the				
date shown below, this correspondence is being submitted as				
1 indicated below:				
I mailed or deposited with the United States Postal Service with				
- Chairm				
Mail Stop Amendment, Commissioner for Pasents, P. O. Bex 1450,				
A1Aris VA 22313-1450				
Ix I faculative transmitted to the U.S. Patent and Trademark Office				
via fax manther (571) 273 \$300				
Horse F. McBride A3,784 Nonse Registration No (if applicable)				
Noneo Registration No (if applicable)				
Signature Signature				
September 15, 105				
Date				

10:16:19

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/662,644

Applicant(s)

Haught et al.

Filed

September 15, 2003

Title

Non-Halogenated Antibacterial Agents and Processes For

**Making Same** 

TC/A.U.

1616

Examiner

Alton Nathaniel Pryor

Conf. No.

9385

Docket No.

8170XR

Customer No.

27752

## RESPONSE AND ELECTION UNDER 37 CFR §1.143

## AMENDMENT AND REPLY TO 1ST OFFICE ACTION UNDER 37 CFR §1.111(b) and (c)

Commissioner for Patents

VIA FACSIMILE 571/273-8300 and 571/273-0621

Dear Sir:

#### INTRODUCTORY REMARKS

In response to the Office Action of September 7, 2005, the time for response being extended by (0) zero months, please reconsider such application in view of the following amendments and remarks.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 8 of this paper.

Page 1 of 12